Cyolo Unveils Major New Capabilities, Expanding Secure Remote Access Coverage for OT and Cyber-Physical Systems
16.6.2025 15:52:00 EEST | Business Wire | Press release
Cyolo, the leading provider of secure remote privileged access for operational technology (OT) and cyber-physical systems (CPS), has announced the launch of several major new capabilities, headlined by Cyolo Third-Party VPN Control (patent pending). This groundbreaking capability within the company’s Cyolo PRO (Privileged Remote Operations) solution delivers visibility and access control for enforced third-party VPN and direct connections without requiring changes to production infrastructure or vendor workflows.
In today’s increasingly connected industrial environments, even organizations with mature security programs face a critical blind spot: third-party connections they cannot govern or even see. Some vendors insist on using their own legacy VPNs, site-to-site tunnels, or proprietary ‘black box’ gateways on OT networks, forcing plant managers and industrial operators to accommodate external methods that operate outside of their control. These opaque and unmanaged pathways pose significant risks, leaving organizations unaware of who is connecting, when, where, and what activities are occurring inside their most sensitive networks.
The new Third-Party VPN Control capability helps close this gap by enabling visibility and access policy enforcement, even when externally managed VPNs or hardware gateways are used.
This Cyolo PRO release includes additional enhancements, each tailored to address critical access and collaboration needs in cyber-physical environments:
- Instant Collaboration Link: A browser-based, one-time secure link, enabling session owners to invite multiple external participants, i.e., vendors, auditors and engineers into RDP, SSH, or VNC sessions including security controls without agent installations.
- Secure Remote Assistance: Native, secure technical support for both user-initiated and helpdesk-initiated assistance sessions, allowing organizations to deliver timely support while maintaining complete security and operational governance.
- Asset Access Hub: Provides a comprehensive view of assets across various business contexts (e.g., function, vendor) and technical attributes (e.g., IP address, zone, access status). This empowers administrators to manage access based on relevant context and quickly assign accurate, role-based permissions.
As always, Cyolo PRO integrates seamlessly with legacy remote connectivity setups and supports Zero Trust principles by segmenting access.
“In today’s virtual environments, third-party vendors are essential for the unbroken continuity of industrial operations and critical infrastructure—both vital for the economy and national security. However, third-party access methods too often introduce unacceptable risks,” said Almog Apirion, CEO and Co-Founder of Cyolo. “We are always thinking about the real-world challenges our customers face and endlessly innovating to solve those problems. This latest advance represents the next step in the transformation of OT and CPS access, making it more agile, secure, and seamless for administrators and end users, without forcing vendors to change the tools they rely upon.”
With these advanced new capabilities, organizations gain:
- Zero Trust for VPNs: Segments and restricts third-party access for approved assets, reducing lateral movement risk.
- Access Visibility: Real-time visibility into incoming access sessions.
- Compliance-Ready Architecture: Aligns with NERC CIP, ISA/IEC 62443, ISA99, and NIST 800-82 standards.
- Broad Compatibility: Integrates with all legacy remote connectivity suppliers.
To learn more about Cyolo PRO’s new Third-Party VPN Control and full range of capabilities, visit https://cyolo.io.
About Cyolo
Cyolo provides secure remote privileged access for cyber-physical systems. The Cyolo PRO (Privileged Remote Operations) solution enables industrial enterprises to connect employees and third-party vendors to critical assets in ways that are secure, safe, and surprisingly simple.
Cyolo offers stronger security and more control than traditional secure remote access (SRA), while simultaneously improving operational agility and productivity. Cyolo PRO adapts to any environment, deploys without disruptions or infrastructure changes, and offers capabilities such as privileged access controls, zero-trust connectivity, identity-based access for legacy systems, and centralized management across multiple sites.
Former CISO Almog Apirion co-founded Cyolo in 2020. Frustrated by the limitations of existing SRA tools, he joined forces with industry veterans to build a solution that meets the distinctive access needs of OT environments and cyber-physical systems. With headquarters in Israel and a strong presence in the US and EMEA, Cyolo’s network of employees, customers, and partners stretches around the world. To learn more, visit https://cyolo.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250613015918/en/
Contacts
Media contact
Gabi Benedyk
Headline Media
gabi@headline.media
IL: +972 58 484 7380
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom